BELL’s new partnership will shed light on further potentials for digital therapeutics by overcoming limitations of current approaches.
Seoul, South Korea–(Newsfile Corp. – August 16, 2022) – BELL Therapeutics Inc. (Seoul, S.Korea) recently has agreed to a R&D partnership with Prof. Ki-Young Jung, M.D., Ph.D., in the Department of Neurology, Seoul National University Hospital. BELL Therapeutics is a tech-company developing next generation digital therapeutics (DTx). This R&D partnership will provide BELL with an expertise in clinical knowledge about sleep disorder and brain diseases, and facilitate its clinical research and development of relevant DTx.
Towards next-generation digital therapeutics – BELL Therapeutics announces new partnership with Prof. Jung, Seoul National University Hospital
To view an enhanced version of this graphic, please visit:
BELL intends to present next generation DTx by overcoming limitations of existing DTx. While many DTx focus on extending traditional Cognitive Behavioral Therapy in a form of software, BELL steps further by presenting a software that implements a medicine’s acting mechanism. Such approach does not have to rely on languages when treating patients, and is conjectured to make immediate treatment effects like actual medicines.
Jonghwa Park, the founder of BELL Therapeutics Inc., said that “DTx has successfully proven its usefulness and potential to the providers of this service such as the regulatory agency, insurance companies, hospitals, and doctors, but the actual receivers of the service, the patients, remain doubtful of the practicality of DTx,” and that “our goal is to develop a next generation DTx that patients are eager to use.” Consistent with this, BELL has approached differently by redesigning the rationale and technology of their pipeline.
Prof. Ki-Young Jung mentioned that “BELL’s technology is managing hyper-arousal of body and brain by activating certain regions of brain with sound and software” and that “its acting mechanism has promising potential for patients with sleep disorder such as insomnia.” Ki-Young Jung is a professor in the Department of Neurology, Seoul National University Hospital and a fellow member of American Academy of Sleep Medicine. His research area includes sleep disorders and epilepsy, and has recently focused on exploring a possible bio-marker of REM sleep disorder, which is also suggested as a preceding symptom of Parkinson’s disease. He also was a president of the Korean Society of Sleep Medicine.
About the founder: Jonghwa Park studied music composition and cognitive neuroscience of music at Seoul National University, and majored electrical & computer engineering at Seoul National University Graduate School of Engineering. Based on his experience at Korea Institute of Science and Technology, He founded Brain Music Lab Inc. (Seoul, S. Korea) with neuroscientists, musicians, and engineers. His collaborations with major firms and artists in South Korea include a project with Hyundai Motor Co. presented at Seoul Arts Center, which he took part as the director of sound and music. Then he founded BELL Therapeutics Inc. to contribute in innovating healthcare services by developing softwares that can fight mankind diseases.
Name: Jonghwa Jeongrok Park
Email: [email protected]
Organization: BELL Therapeutics Inc.
Phone: +82 10-9629-6810
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/133969
Vaccines, treatments and tests will soon all be commercially available. But what that means for consumers' out-of-pocket costs is unclear.
The FDA approved the sale of over-the-counter hearing aids, allowing millions of Americans to buy hearing aids without seeing an audiologist to improve access to hearing aids, which may lower costs for millions of Americans. The rules, which take effect in mid-October, apply to hearing aids for people with mild to moderate hearing loss. The aids will be available directly from stores or online without medical exams, a prescription, or audiologist fitting adjustment. White House National Economic
More than two years into the pandemic, hospitalized patients with severe cases may get a game-changing treatment.
Blueprint unveiled the "long-awaited" results of its study in indolent systemic mastocytosis on Wednesday, and the biotech stock crashed.
A Bedford-based gene therapy firm is pausing clinical development of one gene therapy to focus on a similar, but potentially broader, treatment.
By John Vandermosten, CFA NYSE:PLX READ THE FULL PLX RESEARCH REPORT Second Quarter Financial and Operational Review Protalix Biotherapeutics, Inc. (NYSE:PLX) announced its 2Q:22 financial and operational results in an August 15, 2022 press release and filing of Form 10-Q . The materials were followed by a conference call which discussed recent achievements, regulatory updates and drivers for
As one of the leading genetic medicine companies on the planet, Sarepta Therapeutics is on the forefront of many nerdy advances. It was the first drug developer to earn U.S. Food and Drug Administration (FDA) approval for products treating Duchenne muscular dystrophy (DMD), a rare genetic disorder impacting muscle development. Meanwhile, Sarepta Therapeutics currently boasts over 37 pipeline programs, including 21 assets in gene therapy alone.
The plaintiff in the first lawsuit over the heartburn drug Zantac scheduled to go to trial has agreed to drop his case, according to his attorney and drugmakers named as defendants. Tuesday's news came days after shares of GlaxoSmithKline Plc, Sanofi SA, Pfizer Inc and Haleon Plc were hit by mounting investor concern about thousands of lawsuits claiming the drug, which U.S. regulators pulled from the market in 2020, causes cancer. The plaintiff, Joseph Bayer, alleged he developed esophageal cancer from taking over-the-counter Zantac.
Tuesday's news came days after shares of GlaxoSmithKline Plc , Sanofi SA, Pfizer Inc and Haleon Plc were hit by mounting investor concern about thousands of lawsuits claiming the drug, which U.S. regulators pulled from the market in 2020, causes cancer. The plaintiff, Joseph Bayer, alleged he developed esophageal cancer from taking over-the-counter Zantac. Alexandra Walsh, an attorney for Bayer, said her client could not proceed for "personal health reasons" but had the right to refile his case within a year.
Is Merck stock a buy as reports suggest it could put up $40 billion to acquire Seagen? Is MRK stock a buy right now?
Gilead announced Monday that the overall survival rate for patients taking the drug had achieved statistical significance.
Kate Hermans has taken over the reins of Ambrx Biopharma Inc (NASDAQ: AMAM) as interim CEO following the abrupt departure of Feng Tian, who also served as chairman of the board of directors. The company did not provide information regarding the departure of Tian, who has been with Ambrx for nearly two decades. Interim CEO Hermans joined Ambrx last month as a board of directors member. Bristol Myers Squibb Co Inc (NYSE: BMY) moved out from a heart failure drug collaboration with Ambrx Biopharma i
Novartis (NVS) suffers a setback as canakinumab fails to meet the primary goal in yet another study for lung cancer.
Is Johnson & Johnson stock a buy after it announced plans to switch to cornstarch-based baby powder? Is JNJ stock a buy now?
Based on results from a late-stage study, Sanofi (SNY) will discontinue the development of its breast cancer candidate, amcenestrant.
A pregnant and parentless 16-year-old in Florida may be forced to give birth after an appeals court ruled she was not “sufficiently mature to decide whether to
FDA Approves First Cell-Based Gene Therapy to Treat Adult and Pediatric Patients with Beta-thalassemia Who Require Regular Blood TransfusionsPR NewswireSILVER SPRING, Md. 17, 2022 /PRNewswire/ — Today, the U.
There’s a special type of childhood disappointment in arriving at a rich person’s doorstep on Halloween only to receive a miniature candy bar. I imagine that whoever shows up for an evening at the Oz family home is similarly let down when they lay eyes on the platter of crudités.
The Social Security Administration has added 12 new health conditions under its Compassionate Allowances program, meaning people with these conditions now have faster access to Social Security…
Though the United States appears to be coming out of the worst of the pandemic, COVID-19 isn't going away any time soon. And there remains the continued risk of another surge as more states relax…